You are here

Management of Targeted Therapies: adverse events with immune checkpoint inhibitors – how to manage patients in clinical practice?

By Stéphane Champiat, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

33 - Stéphane Champiat ANG

Cancer immunotherapy targets the immune system, leading to a novel spectrum of adverse events – the so-called immune-related adverse events. While early adverse events are rare with immune checkpoint inhibitors, delayed and post-treatment adverse events can occur as these inhibitors activate the immune system and thus have a more global effect; the treatment sometimes also activates auto-reactive clones which may trigger an autoimmune response. Stéphane Champiat provides an overview of the clinical development of immune checkpoint inhibitors and the kinetics of appearance of immune-related adverse events such as rash, pruritus, diarrhea, colitis, liver toxicity and hypophysitis. He identifies potential risk factors for immune-related toxicity and presents a risk management algorithm – early detection of autoimmune diseases is important because their treatment becomes more and more difficult as they progress. Immune-related toxicity can affect all organs; therefore, it is vital that physicians remain vigilant and patients are educated with regard to signs and symptoms of autoimmune diseases.

 

Stéphane Champiat, Institut G. Roussy, Villejuif, France

 

Search this site

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

NEW! Free access to the digital version of a new publication in Cancer Supportive Care


Cancer cachexia: mechanisms and progress in treatment

Authors: Egidio Del Fabbro, Kenneth Fearon, Florian Strasser

This book was supported by an educational grant from Helsinn Healthcare SA.

Featured videos

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share